Bluejay Diagnostics, Inc. (BJDX) Fair Value 2026

BJDX · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.4 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (47/100)

Quick Summary — As of 2026-08-27, Bluejay Diagnostics, Inc. (BJDX) trades at $0.91. QOC: 4.4/10. Value Trap Risk: 47/100 (WARN). 0/13 models active.

Key Facts

Ticker
BJDX
Price
$0.91
Quality Score
4.4/10
Value Trap Risk
47/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 47 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give BJDX?

0 Intrinsic Value Models vs. Current Price ($0.91)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Bluejay Diagnostics, Inc. (BJDX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bluejay Diagnostics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About BJDX?

0 of 13 models are currently active for BJDX. See which stocks rank higher →

How Does BJDX Rank in Medical Devices?

Among 157 Medical Devices stocks, BJDX ranks #137 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

Bluejay Diagnostics, Inc.'s positioning within the Medical Devices segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is BJDX a Value Trap?

CirclFi's Value Trap algorithm assigns BJDX a score of 47/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Bluejay Diagnostics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Bluejay Diagnostics, Inc. earns a quality score of 4.4/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BJDX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bluejay Diagnostics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

MODDModular Medical, Inc.QOC 4.4PMIPicard Medical, Inc.QOC 4.4POASPhaos Technology Holdings (CaymQOC 4.5ADGMAdagio Medical Holdings, Inc.QOC 4.3CSDXCS Diagnostics Corp.QOC 4.5POSCPositron CorporationQOC 4.3XTNTXtant Medical Holdings, Inc.QOC 8.4HYPRHyperfine, Inc.QOC 6.8ADMTADM Tronics Unlimited, Inc.QOC 5.8IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: MODD · PMI · POAS · ADGM · CSDX · POSC · XTNT · HYPR · ADMT · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to BJDX?

7 companies across all industries closest to BJDX’s Quality of Company score of 4.4/10.

PTHSPelthos Therapeutics Inc.QOC 4.4JAGXJaguar Health, Inc.QOC 4.4MDAMDA Space Ltd.QOC 4.4CTORCitius Oncology, Inc.QOC 4.4NWBONorthwest Biotherapeutics, Inc.QOC 4.4PMCBPharmaCyte Biotech, Inc.QOC 4.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PTHS · JAGX · MDA · CTOR · NWBO · PMCB · NVDA

Where Does BJDX Sit in CirclFi's Medical Devices Rankings?

BJDX is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Bluejay Diagnostics, Inc.’s Valuation?

What is Bluejay Diagnostics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Bluejay Diagnostics, Inc. (BJDX). The Quality of Company score is 4.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BJDX overvalued or undervalued right now?

At $0.91, 0 of 0 active models suggest BJDX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Bluejay Diagnostics, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 4.4 mean for BJDX?

Bluejay Diagnostics, Inc.'s QOC of 4.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BJDX?

CirclFi analyzes BJDX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is BJDX a value trap in 2026?

Bluejay Diagnostics, Inc.'s Value Trap score is 47/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Bluejay Diagnostics, Inc. (BJDX) a Quality of Company score of 4.4/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/BJDX/ · Methodology
Primary sources for this BJDX valuation
  • Financial statements: Bluejay Diagnostics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001704287) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BJDX as of ; valuations recomputed .